The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
Singh
Ajay K
AK
D000740:Anemia / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D002908:Chronic Disease; D003257:Consumer Product Safety; D004348:Drug Labeling; D019317:Evidence-Based Medicine; D006397:Hematinics / Q000009:adverse effects / Q000627:therapeutic use*; D006454:Hemoglobins / Q000378:metabolism*; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000150:complications / Q000628:therapy*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D015854:Up-Regulation
D006397:Hematinics; D006454:Hemoglobins